…with an initial focus on China, where positive market conditions mirror early North American markets.
We are developing large-scale EU GMP-certified processing and production infrastructure and are preparing to distribute branded consumer products in Asia.
Combining Western industry expertise with Asian efficiencies and attractive marketplace opportunities, we are charting an early course to build significant value in a license-constrained environment.
Large-scale, low-cost production of pharmaceutical grade CBD and other non-psychoactive cannabinoids to supply the global market
Distributing leading CBD brands within domestic Asian markets
Investing strategically into market-leading Asian hemp and cannabis companies
We are creating positive change by advancing the future of
Timeline To Global Producer
Develop EU GMP-certified facilities for production and export of bulk ingredients to global markets, while focusing distribution efforts on Western brands in Chinese domestic market
Opportunistically deploy capital and continue building operations within China and across Asia, establishing a robust portfolio of strategic assets as the market matures
Continue expansion while exploring strategic capital market opportunities including M&A and or public listing in the US or Asia